Yersiniosis Diagnostics and Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Yersiniosis Diagnostics and Treatment Market is Segmented by Bacterial Species (Yersinia enterocolitica, Yersinia pseudotuberculosis), Product Type (Diagnosis Technique and Therapeutics), Diagnosis Technique (Real-Time PCR, ELISA, Immunoassay, Protein Microarray, Stool Culture, and Other Diagnosis Technique), Therapeutics (Aminoglycosides, Sulfonamides, Cephalosporins, Fluoroquinolones, Tetracyclines, and Other Therapeutics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Market Snapshot

1
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Yersiniosis diagnostics and treatment market is expected to register a CAGR of 6.8% over the forecast period, 2022-2027.

The COVID-19 outbreak is a rare public health concern that has had a huge global impact on the market globally as hospital and healthcare services were severely curtailed due to social exclusion and the supply chain was hampered. The exceptional rise in coronavirus-infected patients, and limited access to alternate primary care services, sped up the decline in non-COVID-19-related diagnoses, such as Yersiniosis. The reported cases of Yersiniosis were fewer in 2020 than in 2019 due to the decrease in footfall in hospitals and clinics. For instance, according to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the reported cases of Yersiniosis in the European Union decreased in 2020 as compared to the previous year. However, with the decreasing COVID-19 cases and large-scale vaccination, the diagnosis of Yersiniosis is expected to increase and the studied market is anticipated to regain its potential over the forecast period.

Therefore, the Yersiniosis diagnostics and treatment market will impede around the world with the emergence of the COVID-19 pandemic, but it will have a positive impact on the decreasing cases of COVID-19. After the COVID-19's impact has diminished, the market in some regions will gradually demonstrate consistent growth.

The market is expected to grow due to the high prevalence of Yersiniosis in Northern Europe and countries in Central Europe and improved diagnostic techniques. According to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the overall notification rate of 1.7 per 100 000 population remained stable from 2015 to 2020 in the European Union. But the highest notification rates were found in countries of Northern and Central Europe. According to the same source, in 2020 the highest Incidence rate of 7.09 per 100 000 population was found in Denmark. Thus, the above increase in the prevalence of Yersiniosis in some regions may have a positive impact on the Yersniosis diagnosis market and treatment during the forecast period.

One of the major reasons for Yersiniosis's spread is the consumption of contaminated food. The symptoms of infected young children include fever, abdominal pain, and diarrhea. In May 2022, World Health Organization published that, children under 5 years of age carry 40% of the foodborne disease burden, with 125 000 deaths every year. This increase in foodborne diseases may indirectly have a positive impact on enteric bacterial infections like Yersiniosis. Thus, the increase in foodborne diseases may help the growth of the Yersiniosis diagnostics and treatment market in the studied period.

The advent of more advanced diagnostic technologies like real‐time PCR, ELISA, and Luminex Immunoassay helps in the identification of enteropathogenic Yersinia species by differentiation of Yersinia enterocolitica and Yersinia pseudotuberculosis. These improved diagnosis methods help in Yersiniosis diagnostics and treatment market help to witness high growth over the forecast period. However, a lack of awareness in developing and underdeveloped countries on Yersiniosis disease, diagnosis, and treatment will impede the market.

Scope of the Report

As per the scope of the report, Yersiniosis is an infection caused most often by eating raw or undercooked pork contaminated with Yersinia enterocolitica bacteria. Yersinia enterocolitica has six biotypes, of which five are considered pathogenic in humans (biotypes 1B, 2, 3, 4, and 5). The Yersiniosis Diagnostics and Treatment Market are segmented by Bacterial Species (Yersinia enterocolitica, Yersinia pseudotuberculosis), Product Type (Diagnosis Technique and Therapeutics), Diagnosis Technique (Real-Time PCR, ELISA, Immunoassay, Protein Microarray, Stool Culture, and Other Diagnosis Technique), Therapeutics (Aminoglycosides, Sulfonamides, Cephalosporins, Fluoroquinolones, Tetracyclines, and Other Therapeutics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Bacterial Species
Yersinia enterocolitica
Yersinia pseudotuberculosis
By Product Type
Diagnosis Technique
Real-Time PCR
ELISA
Immunoassay
Protein Microarray
Stool Culture
Other Diagnosis Technique
Therapeutics
Aminoglycosides
Sulfonamides
Cephalosporins
Fluoroquinolones
Tetracyclines
Other Therapeutics
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

ELISA is Expected to Have a Major Share Over the Forecast Period

The disease diagnosis segment is expected to hold a major share due to the increasing application of enzyme-linked immunosorbent assay (ELISA) tests in the diagnosis of Yersiniosis. It is a commonly used in vitro test to detect antibodies in the blood. ELISA test can be applied in many diagnostic tests like detection and measurement of antibodies in the sample against infectious disease, tumor markers, hormone levels, and drug abuse. ELISA for Yersinia is a quantitative in vitro test for the detection and safe identification of antibodies against plasmid-coded virulence proteins. Thus, quantitative ELISA helps in diagnosing the disease severity which is a significant factor for the growth of the Yersiniosis diagnostics market in the forecast period.

In February 2022, the National Library of Medicine published an article that depicts the advantages and factors that can interfere with ELISA in diagnosing infections. Similarly, the National Library of Medicine published in April 2022, that serologic techniques to identify IgG, IgA, and IgM, such as ELISA and immunoblotting, are extensively utilized in Europe and Japan but less so in the United States. The data helps for differentiation of Yersinia enterocolitica and Yersinia pseudotuberculosis using disease-specific antigens in the ELISA test. These advancements in the ELISA will improve the growth of the market in the forecasted period.

Age Specific Notification Rate of Yersiniosis

North America is Expected to Dominate the Market Over the Forecast Period

North America is anticipated to have a significant share in the market, owing to the well-established healthcare infrastructure, sophisticated diagnostics, and significant notification rates in North American regions.

In 2020, Public Health Ontario published that, there are about 197 cases of Yersiniosis and 9 hospitalizations with a notification rate of 1.3 per 100 000 population. According to the Centers for Disease Control and Prevention reviewed in 2019, Yersiniosis is most frequently reported in northern Europe (especially Scandinavia), Japan, and Canada. It is not a condition that is required to be reported in the United States. About 92% of infections in the United States with known species information are caused by Yersinia enterocolitica, which is also responsible for an estimated 117,000 illnesses, 640 hospitalizations, and 35 fatalities annually. The significant cases reported in North America may also have a significant growth in the forecast market.

Yersiniosis Diagnostics and Treatment Market

Competitive Landscape

The Yersiniosis diagnostics and treatment are fragmented in nature due to the presence of several companies operating globally. The major players include Surmodics IVD, Inc, Mikrogen GmbH, CerTest Biotec, Laboratory Corporation of America Holdings, Hologic, Inc, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Thermo Fisher Scientific, Virchow Laboratories Limited, Zhejiang Jinhua CONBA Bio-pharm.

Recent Development

  • In May 2021, CerTest announced that it has reached the final stage in the extension of its production capacity and the enlargement of the plant located in San Mateo de Gallego, in Zaragoza. In 2021, the company also started working on new production lines for various diagnostic tests.
  • In November 2019, CerTest obtained the Aragon Social Responsibility mark from the government of Aragon which implies the confirmation of CerTest Biotec’s commitment to the social principles of awareness, commitment, transparency, and that make up the Aragon Social Responsibility Plan.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Prevalence of Yersiniosis

      2. 4.2.2 Advent of More Advanced Diagnostic Technologies

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness in Developing and Underdeveloped Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Bacterial Species

      1. 5.1.1 Yersinia enterocolitica

      2. 5.1.2 Yersinia pseudotuberculosis

    2. 5.2 By Product Type

      1. 5.2.1 Diagnosis Technique

        1. 5.2.1.1 Real-Time PCR

        2. 5.2.1.2 ELISA

        3. 5.2.1.3 Immunoassay

        4. 5.2.1.4 Protein Microarray

        5. 5.2.1.5 Stool Culture

        6. 5.2.1.6 Other Diagnosis Technique

      2. 5.2.2 Therapeutics

        1. 5.2.2.1 Aminoglycosides

        2. 5.2.2.2 Sulfonamides

        3. 5.2.2.3 Cephalosporins

        4. 5.2.2.4 Fluoroquinolones

        5. 5.2.2.5 Tetracyclines

        6. 5.2.2.6 Other Therapeutics

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Surmodics IVD, Inc

      2. 6.1.2 Mikrogen GmbH

      3. 6.1.3 CerTest Biotec

      4. 6.1.4 Laboratory Corporation of America Holdings

      5. 6.1.5 Hologic, Inc

      6. 6.1.6 Bio-Rad Laboratories, Inc

      7. 6.1.7 F. Hoffmann-La Roche Ltd

      8. 6.1.8 Pfizer Inc

      9. 6.1.9 Virchow Laboratories Limited

      10. 6.1.10 Zhejiang Jinhua CONBA Bio-pharm

      11. 6.1.11 Thermo Fisher Scientific

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Yersiniosis Diagnostics and Treatment Market market is studied from 2019 - 2027.

The Global Yersiniosis Diagnostics and Treatment Market is growing at a CAGR of 6.8% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Surmodics IVD, Inc, Mikrogen GmbH, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings, CerTest Biotec are the major companies operating in Global Yersiniosis Diagnostics and Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!